

Lumvoa™ (Veligrotug-Vvze) and Tepezza® (Teprotumumab-Trbw)

Policy Number: 2026D0089M
Effective Date: October 1, 2026

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	2
Background	3
Benefit Considerations	3
Clinical Evidence	3
U.S. Food and Drug Administration	5
Centers for Medicare and Medicaid Services	5
References	5
Policy History/Revision Information	6
Instructions for Use	7

Related Commercial Policy

- [Provider Administered Drugs – Site of Care](#)

Community Plan Policy

- [Lumvoa™ \(Veligrotug-Vvze\) and Tepezza® \(Teprotumumab-Trbw\)](#)

Application

UnitedHealthcare Commercial

This Medical Drug Policy applies to UnitedHealthcare Commercial benefit plans.

UnitedHealthcare Individual Exchange

This Medical Drug Policy applies to Individual Exchange benefit plans.

Coverage Rationale

[See Benefit Considerations](#)

Lumvoa™ (veligrotug-vvze) has been added to the Review at Launch program. Some members may not be eligible for coverage of this medication at this time. Refer to the Medical Benefit Drug Policy titled [Review at Launch for New to Market Medications](#) for additional details.

Thyroid Eye Disease

Lumvoa and Tepezza are proven for the treatment of thyroid eye disease. Lumvoa and Tepezza are medically necessary when all of the following criteria are met:

- Diagnosis of thyroid eye disease (TED); and
- Presence of moderately to severe disease, associated with at least **one** of the following:
 - **Both** of the following:
 - Presence of symptomatic, active disease; and
 - **One** of the following:
 - Lid retraction ≥ 2 mm; or
 - Moderate or severe soft tissue involvement; or
 - Proptosis ≥ 3 mm above normal for race and sex; or
 - Diplopia
 - or
 - **Both** of the following:

- Presence of stable, chronic (inactive) disease; **and**
- **One** of the following:
 - Greater than or equal to 3 mm in proptosis from before diagnosis of TED; **or**
 - Proptosis $\geq$ 3 mm above normal values for race and sex (i.e., 19 and 21 mm for white female and male patients, respectively; and 23 and 24 mm for black female and male patients, respectively)

and

- **One** of the following:
 - Presence of either significant proptosis or diplopia; **or**
 - **Both** of the following:
 - Absence of either significant proptosis or diplopia; **and**
 - History of intolerance, failure, or contraindication to oral or intravenous glucocorticoids (e.g., prednisone, methylprednisolone) (For Medicare reviews, refer to the [CMS](#) section.*)

and

- **One** of the following:
 - Patient is euthyroid [defined as free triiodothyronine (T3) and thyroxine (T4) levels within the normal limits]; **or**
 - Presence of mild hypo- or hyperthyroidism [defined as free (T3) and (T4) levels less than 50% above or below the normal limits] and patient is undergoing treatment to correct the mild hypo- or hyperthyroidism to maintain a euthyroid state

and

- Prescribed by an endocrinologist or ophthalmologist; **and**
- **One** of the following:
 - For Lumvoa, patient has not previously received Tepezza (teprotumumab-trbw); **or**
 - For Tepezza, patient has not previously received Lumvoa (veligrotug-vvze)

and

- Patient will not be using Lumvoa or Tepezza in combination with another biologic immunomodulator [e.g., rituximab (Rituxan®, Ruxience®, Truxima®, Riabni®), Actemra® (tocilizumab), Kevzara® (sarilumab)]; **and**
- Dosing is in accordance with the U.S. Food and Drug Administration (FDA)–approved labeling; **and**
- Authorization is limited to a maximum of 5 lifetime doses of Lumvoa and 8 lifetime doses of Tepezza

Reauthorization/Continuation of Care Criteria

Clinical benefit beyond 5 lifetime infusions of Lumvoa and 8 lifetime infusions of Tepezza has not been demonstrated in phase 3 clinical studies. Therefore, treatment exceeding these limits is considered unproven and not medically necessary.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other policies and guidelines may apply.

HCPSC Code	Description
J3241	Injection, teprotumumab-trbw, 10 mg
J3490	Unclassified drugs
J3590	Unclassified biologics

Diagnosis Code	Description
E05.00	Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
E05.01	Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm
H05.20	Unspecified exophthalmos
H05.211	Displacement (lateral) of globe, right eye
H05.212	Displacement (lateral) of globe, left eye
H05.213	Displacement (lateral) of globe, bilateral
H05.219	Displacement (lateral) of globe, unspecified eye

Diagnosis Code	Description
H05.221	Edema of right orbit
H05.222	Edema of left orbit
H05.223	Edema of bilateral orbit
H05.229	Edema of unspecified orbit
H05.231	Hemorrhage of right orbit
H05.232	Hemorrhage of left orbit
H05.233	Hemorrhage of bilateral orbit
H05.239	Hemorrhage of unspecified orbit
H05.241	Constant exophthalmos, right eye
H05.242	Constant exophthalmos, left eye
H05.243	Constant exophthalmos, bilateral
H05.249	Constant exophthalmos, unspecified eye
H05.251	Intermittent exophthalmos, right eye
H05.252	Intermittent exophthalmos, left eye
H05.253	Intermittent exophthalmos, bilateral
H05.259	Intermittent exophthalmos, unspecified eye
H05.261	Pulsating exophthalmos, right eye
H05.262	Pulsating exophthalmos, left eye
H05.263	Pulsating exophthalmos, bilateral
H05.269	Pulsating exophthalmos, unspecified eye

Background

Thyroid eye disease (TED) is also known as thyroid associated orbitopathy (TAO) and Grave's orbitopathy (GO). This disease is an autoimmune inflammatory condition affecting the orbit and ocular adnexa of the eye. TED is associated with distinct clinical features, including upper eyelid retraction, restrictive strabismus, and proptosis. TED can threaten vision through compressive optic neuropathy or corneal decompensation from exposure keratopathy.

The mechanism of action of Lumvoa and Tepezza in patients with TED has not been fully characterized. Lumvoa and Tepezza are humanized IgG1 monoclonal antibodies that bind to insulin-like growth factor-1 receptor (IGF-1R) and inhibit IGF-1R signaling by blocking ligand-induced receptor autophosphorylation.

Benefit Considerations

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy.

Clinical Evidence

Lumvoa

The efficacy and safety of Lumvoa was evaluated in 301 patients across 2 randomized, double-masked, placebo-controlled studies: active thyroid eye disease (Study 1: NCT05176639) and chronic thyroid eye disease (Study 2: NCT06021054). Patients were randomized to receive Lumvoa or placebo in a 2:1 ratio. Patients were given intravenous infusions of Lumvoa 10 mg/kg every 3 weeks for a total of 5 infusions. Patients in Study 1 had a clinical diagnosis of thyroid eye disease with onset within 15 months and a clinical activity score of 3 or more. Patients in Study 2 had a clinical diagnosis of thyroid eye disease with onset greater than 15 months and any clinical activity score (0-7). The proptosis responder rate at Week 15 was defined as the percentage of patients with ≥ 2 mm reduction in proptosis in the study eye from baseline, without deterioration in proptosis (≥ 2 mm increase) in the non-study eye. Additional evaluations included

signs and symptoms of thyroid eye disease including diplopia, retrobulbar pain, gaze evoked orbital pain, eyelid swelling, eyelid erythema, conjunctival redness, chemosis, inflammation, clinical activity score, and assessments of quality of life (functional vision and patient appearance).

Lumvoa demonstrated statistically significant improvements in proptosis and diplopia compared with placebo at Week 15. Proptosis responder rates were 70% vs. 5% [95% CI: 65 (52, 78); $p < 0.01$] in Study 1 and 57% vs. 8% [95% CI: 49 (38, 60); $p < 0.01$] in Study 2. Mean changes in proptosis were -2.9 vs. -0.5 [95% CI: -2.4 (-3.0, -1.8); $p < 0.01$] in Study 1 and -2.4 vs. -0.5 [95% CI: -1.9 (-2.4, -1.4); $p < 0.01$] in Study 2. Diplopia responder rates were 59% vs. 20% [95% CI: 39.2 (18.8, 59.6); $p < 0.01$] in Study 1 and 56% vs. 25% [95% CI: 30.9 (12.3, 49.5); $p < 0.01$] in Study 2. Diplopia resolution rates were 49% vs. 12% [95% CI: 37.7 (18.9, 56.6); $p < 0.01$] in Study 1 and 32% vs. 14% [95% CI: 17.7 (1.6, 33.9); $p < 0.01$] in Study 2. Among Week 15 responders, proptosis and diplopia improvements were maintained through Week 52 in a substantial proportion of patients.

The most common adverse reactions ($\geq 10\%$) that occurred at greater incidence in the Lumvoa group than in the control group during the treatment period of Studies 1 and 2 include: muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, and ear discomfort. In addition, menstrual disorders (amenorrhea, menstruation irregular, dysmenorrhea, menstruation delayed, intermenstrual bleeding, and menstrual disorder) were reported in approximately 29% (24/82) of menstruating women treated with Lumvoa compared to 6% (2/33) of patients treated with placebo in the clinical trials.

Tepezza

The efficacy and safety of teprotumumab was evaluated in 2 randomized, double-masked, placebo-controlled trials in 171 patients diagnosed with thyroid eye disease (TED). Patients were randomized to either receive teprotumumab ($n = 84$) or placebo ($n = 87$) in a 1:1 ratio. Patients receiving teprotumumab were infused 10mg/kg for the first infusion and 20mg/kg for the remaining 7 infusions every 3 weeks for a total of 8 infusions. The proptosis responder rate at week 24 was defined as the percentage of patients with ≥ 2 mm reduction in proptosis in the study eye from baseline, without deterioration in the non-study eye (≥ 2 mm increase) in proptosis. Additional evaluations included signs and symptoms of TED including pain, gaze evoked orbital pain, swelling, eyelid erythema, redness, chemosis, inflammation, clinical activity score and assessments of functional vision and patient appearance.

In study 1, in the intention-to-treat population, 29 of 42 patients who received teprotumumab (69%), as compared with 9 of 45 patients who received placebo (20%), had a response at week 24 ($p < 0.001$). Therapeutic effects were rapid; at week 6, a total of 18 of 42 patients in the teprotumumab group (43%) and 2 of 45 patients in the placebo group (4%) had a response ($p < 0.001$). Differences between the groups increased at subsequent time points. The only drug-related adverse event was hyperglycemia in patients with diabetes; this event was controlled by adjusting medication for diabetes.

In study 2 ($n = 83$), at week 24, the percentage of patients with a proptosis response was higher with teprotumumab than with placebo [83% (34 patients) vs. 10% (4 patients), $p < 0.001$], with a number needed to treat of 1.36. All secondary outcomes were significantly better with teprotumumab than with placebo, including overall response [78% of patients (32) vs. 7% (3)], Clinical Activity Score (CAS) of 0 or 1 [59% (24) vs. 21% (9)], the mean change in proptosis (-2.82 mm vs. -0.54 mm), diplopia response [68% (19 of 28) vs. 29% (8 of 28)], and the mean change in GO-QOL overall score (13.79 points vs. 4.43 points) ($p \leq 0.001$ for all). Reductions in extraocular muscle, orbital fat volume, or both were observed in 6 patients in the teprotumumab group who underwent orbital imaging. Most adverse events were mild or moderate in severity; two serious events occurred in the teprotumumab group, of which one (an infusion reaction) led to treatment discontinuation. Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, clinical activity score, diplopia, and quality of life than placebo; serious adverse events were uncommon.

The efficacy and safety of teprotumumab in TED patients regardless of disease activity or duration was established by a randomized, double-masked, placebo-controlled, parallel-group, multicenter, Phase 4 clinical trial that evaluated adult patients with chronic TED and low levels of disease activity. The primary efficacy objective was to measure the effect of teprotumumab versus placebo in the change of proptosis measurements in the study eye from baseline at Week 24. All study participants were required to have an initial diagnosis of TED two to 10 years prior to screening, and a CAS of ≤ 1 in both eyes for at least one year prior to screening or all of the following one year prior to screening: no progression in proptosis, no progression in diplopia and no new inflammatory TED symptoms. Participants could not have had prior orbital irradiation, orbital decompression surgery or strabismus surgery. The mean duration of disease for teprotumumab and placebo patients was 5.1 years (SD 1.88) and 5.4 years (SD 1.61), respectively. The mean CAS for teprotumumab and placebo patients was 0.3 (SD 0.47) and 0.5 (SD 0.51), respectively. At Week 24, per the pre-specified primary analysis method (intent-to-treat), patients treated with teprotumumab achieved a statistically significant reduction in proptosis from baseline compared to those receiving placebo (2.41 mm vs. 0.92 mm; $p = 0.0004$). In addition, in the pre-

specified per-protocol analysis, the differences between patients treated with teprotumamb and patients treated with placebo increased (2.44 mm vs. 0.69 mm; $p = 0.0006$).

Professional Societies

American Thyroid Association and European Thyroid Association

The American Thyroid Association and the European Thyroid Association issued a consensus statement in 2022 for the management of thyroid eye disease. The Task Force notes “active” thyroid eye disease as disease with a clinical activity score (CAS) of ≥ 3 or if the patient has history or documentation of progression of thyroid eye disease based on subjective or objective worsening of vision, soft tissue inflammation, motility, or proptosis. CAS assesses seven items (spontaneous retrobulbar pain, pain on attempted up or lateral gaze, redness of the eyelids, redness of the conjunctiva, swelling of the eyelids, inflammation of the caruncle and/or plica, and conjunctival edema); each item is given one point if present. The severity of disease is divided into three groups: mild (features of disease have a minor impact on daily life insufficient to justify treatment), moderate-to-severe (patient does not have sight-threatening disease but disease has sufficient impact on daily life to justify the risks of medical or surgical intervention), or sight-threatening (patient with dysthyroid optic neuropathy and/or corneal breakdown and/or globe subluxation). Patients with moderate-to-severe TED usually have any one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, proptosis ≥ 3 mm above normal for race and sex, or diplopia (Gorman score 2-3). Pharmacologic treatment includes oral or IV glucocorticoids, mycophenolate, rituximab, Tepezza, and Actemra (tocilizumab IV infusion). Intravenous glucocorticoid (IVGC) therapy is noted as a preferred treatment for active moderate-to-severe TED when disease activity is the prominent feature in the absence of either significant proptosis or diplopia. Tepezza is noted as a preferred therapy, if available, in patients with active moderate-to-severe TED with significant proptosis and/or diplopia. The Task Force used the term ‘significant proptosis’ rather than a numerical threshold (i.e., ≥ 3 mm above the upper limit for race and sex) as a numerical definition would exclude some patients who might otherwise benefit from therapy. In keeping with the definition of moderate-to-severe TED, a degree of proptosis < 3 mm above the upper limit for race and sex would be regarded as ‘significant proptosis’ if it impacted sufficiently on daily life and would justify the risks of treatment.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Lumvoa (veligrotug-vvze) is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.

Tepezza (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease.

Centers for Medicare and Medicaid Services (CMS)

Coverage guidelines for certain Part B drugs may be found in the Medicare Advantage Medical Policy titled [Medications/Drugs \(Outpatient/Part B\)](#). National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. These NCDs/LCDs/LCAs are available at <https://www.cms.gov/medicare-coverage-database/new-search/search.aspx>.

In general, Medicare covers outpatient (Part B) drugs that are furnished “incident to” a physician’s service provided that certain criteria are met, including that the drugs are not usually self-administered by the patients who take them. Refer to the [Medicare Benefit Policy Manual, Chapter 15, §50 - Drugs and Biologicals](#).

*Preferred therapy criteria are not applicable for Medicare Advantage members.

References

1. Lumvoa [prescribing information]. Waltham, MA: Viridian Therapeutics Inc.; June 2026.
2. Tepezza [prescribing information]. Dublin, Ireland: Horizon Therapeutics USA, Inc.; November 2025.
3. Yen MT, Cockerham K, Saeed P, et al. THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. *Ophthalmology*. Published online June 1, 2026.
4. Turbin RE, Cockerham K, Abrams J, et al. THRIVE-2 phase 3 trial of veligrotug (VRDN-001) in chronic thyroid eye disease (TED): efficacy and safety at 15 weeks. *Endocr Pract*. 2025;31(suppl 1). Abstract.

5. Tepezza [prescribing information]. Dublin, Ireland: Horizon Therapeutics USA, Inc.; November 2025.
6. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. *n Engl J Med*. 2017;376(18):1748-1761.
7. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. *n Engl J Med*. 2020;382(4):341-352.
8. Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. *Lancet Diabetes Endocrinol*. 2021;9(6):360-372.
9. Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. *Ophthalmology*. 2022;129(4):438-449.
10. Douglas RS, Couch S, Wester ST, et al. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. *J Clin Endocrinol Metab*. 2023;109(1):25-35.
11. Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. *Thyroid*. 2024;34(7):880-889.
12. Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. *Eur Thyroid J*. 2022;11(6):e220189.
13. de Juan E, Hurley DP, Sapira JD. Racial Differences in Normal Values of Proptosis. *Arch Intern Med*. 1980;140(9):1230-1231.

Policy History/Revision Information

Date	Summary of Changes
10/01/2026	Title Change - Previously titled <i>Tepezza</i>® (<i>Teprotumumab-Trbw</i>) Template Update - Transferred content to shared policy template that applies to both UnitedHealthcare Commercial and Individual Exchange benefit plans - Added <i>Application</i> section to indicate this policy applies to: - UnitedHealthcare Commercial benefit plans - Individual Exchange benefit plans Coverage Rationale Lumvoa - Added language to indicate: - Lumvoa™ (veligrotug-vvze) has been added to the Review at Launch program and some members may not be eligible for coverage of this medication at this time; refer to the Medical Benefit Drug Policy titled <i>Review at Launch for New to Market Medications</i> for additional details - Lumvoa is proven for the treatment of thyroid eye disease; Lumvoa is medically necessary when all of the following criteria are met: - Diagnosis of thyroid eye disease (TED) - Presence of moderately to severe disease, associated with at least one of the following: - Both of the following: - Presence of symptomatic, active disease - One of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, proptosis ≥ 3 mm above normal for race and sex, or diplopia - Both of the following: - Presence of stable, chronic (inactive) disease - One of the following: greater than or equal to 3 mm in proptosis from before diagnosis of TED or proptosis ≥ 3 mm above normal values for race and sex (i.e., 19 and 21 mm for white female and male patients, respectively; and 23 and 24 mm or black female and male patients, respectively) - One of the following: - Presence of either significant proptosis or diplopia - Both of the following: - Absence of either significant proptosis or diplopia

Date	Summary of Changes
	- History of intolerance, failure, or contraindication to oral or intravenous glucocorticoids (e.g., prednisone, methylprednisolone) - One of the following: - Patient is euthyroid [defined as free triiodothyronine (T3) and thyroxine (T4) levels within the normal limits] - Presence of mild hypo- or hyperthyroidism [defined as free (T3) and (T4) levels less than 50% above or below the normal limits] and patient is undergoing treatment to correct the mild hypo- or hyperthyroidism to maintain a euthyroid state - Prescribed by an endocrinologist or ophthalmologist - Patient has not previously received Tepezza (teprotumumab-trbw) - Patient will not be using Lumvoa in combination with another biologic immunomodulator [e.g., rituximab (Rituxan®, Ruxience®, Truxima®, Riabni®), Actemra® (tocilizumab), Kevzara® (sarilumab)] - Dosing is in accordance with the U.S. Food and Drug Administration (FDA)–approved labeling - Authorization is limited to a maximum of 5 lifetime doses of Lumvoa Tepezza - Revised coverage criteria: - Added criterion requiring the patient has not previously received Lumvoa (veligrotug-vvze) - Replaced criterion requiring “authorization <i>will be issued for</i> a maximum of 8 doses per lifetime” with “authorization <i>is limited to</i> a maximum of 8 lifetime doses” Reauthorization/Continuation of Care Criteria - Replaced language indicating “the clinical benefit of Tepezza has not been demonstrated beyond 8 infusions in phase 3 clinical trials; <i>the continued use of Tepezza beyond 8 infusions in the patient’s lifetime is unproven and not medically necessary</i>” with “clinical benefit beyond 5 lifetime infusions of Lumvoa and 8 lifetime infusions of Tepezza has not been demonstrated in phase 3 clinical studies; <i>therefore, treatment exceeding these limits is considered unproven and not medically necessary</i>” Applicable Codes - Added HCPCS codes J3490 and J3590 Supporting Information - Updated <i>Background, Clinical Evidence, FDA, CMS, and References</i> sections to reflect the most current information - Archived previous policy versions 2026D0089L and IEXD0089.12

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its policies and guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence ([Medicare IOM Pub. No. 100-16, Ch. 4, §90.5](#)).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.